SIRT and Peri-immunotherapy : a New Concept

Sponsor
Assistance Publique - Hôpitaux de Paris
Study ID
NCT06971237
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization — DRUG
    Atezolizumab ± Bevacizumab: Peri-immunotherapy with , with or without bevacizumab, given before and after SIRT. \- Yttrium-90 Radioembolization: Selective Internal Radiation Therapy (SIRT) via intra-arterial injection of Yttrium-90 microspheres for liver tumor control
  • Atezolizumab ± Bevacizumab — DRUG
    Standard systemic immunotherapy administered without SIRT, using atezolizumab with or without bevacizumab.

Study Details

The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC stage B or C). Although promising results have been observed in preliminary clinical trials, further research is needed to better understand the underlying mechanisms, optimize treatment protocols, and confirm the long-term efficacy and safety of this combined approach

Key Dates

Start date
Jun 1, 2025
Status verified
Apr 2025
Primary completion
Jul 1, 2026
Completion
Jul 1, 2026

Study Design

Enrollment
60 participants (estimated)

Primary Outcome Measure

Objective Tumor Response Rate [ Time Frame: At 3, 6, 9 and 12 months post-treatment ]

Central Contacts